

VIA FIRST CLASS MAIL

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner of Patents and Trademarks, Washington, D.C. 20231, on October 26, 2001

FULBRIGHT & JAWORSKI L.L.P.

By [Signature]



LUD 5684.2 CIP (10106676) - JEL/NDH

#7

RECEIVED
DEC 11 2001
TEC/CENTER 1600/2900

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : RENAULD, et al.

Serial No. : 09/919,162

Filed : July 31, 2001

For : ISOLATED NUCLEIC ACID MOLECULES WHICH ENCODE A SOLUBLE IL-TIF RECEPTOR OR BINDING PROTEIN WHICH BINDS TO IL-TIF/IL-22, AND USES THEREOF

Art Unit : UNKNOWN

Examiner : UNKNOWN

October 26, 2001

Hon. Commissioner of Patents
and Trademarks
Washington, D.C. 20231

**INFORMATION DISCLOSURE
STATEMENT (37 CFR § 1.56, § 1.97 (c))**

SIR:

In accordance with their duty of disclosure, applicants wish to make the accompanying references of record in this application. None of these references are believed to be prior art. They are provided because they relate generally to the subject matter claimed.

Please charge any fees due herewith to Deposit Account 500624.

International Application No. PCT/US00/32703 to Presnell et al (June 7, 2001) was not available prior to applicants' priority claims. It discloses molecules homologous to molecules of the invention.

International Application No. PCT/US00/14729 to Parham teaches a TIF molecule.

International Application No. PCT/US99/11644 (International Publication No. WO99/61617) to Ruben et al. is entitled "Interleukins 21 and 22." The reference is submitted because there has been confusion in nomenclature, and at one point the molecules of the invention were referred to as "IL-21."

International Application No. PCT/US00/11479 (International Publication No. WO00/65027) to Jacobs, et al., teaches molecules which show homology to IL-22.


Parrish-Novak, et al., "Interleukin-21 and its receptor are involved in NK cell expansion and regulation of lymphocyte function," Nature 408: 57-63 (November 2, 2000). Please see the remarks, supra. regarding confusion in nomenclature with respect to IL-21, and lack of identity of sequences.

Xie, et al., "Interleukin (IL)-22, a Novel Human Cytokine That Signals Through the Interferon Receptor - Related Proteins CRF 2-4 and IL-22R," J. Biol. Chem 275 (40): 21335-21339 (October 6, 2000) IL-22, as disclosed in figure IA, is believed to be identical to human TIF.

It is believed that the claims are patentable over these references, and a holding to that end is urged.

Respectfully submitted,

FULBRIGHT & JAWORSKI L.L.P.

By 
Norman D. Hanson
Reg. No. 30,946

666 Fifth Avenue
New York, New York 10103
(212) 318-3100

Form PTO-1449 (Modified)
(Rev. 11/92)U.S. Dept. of Commerce
Patent and Trademark Office

ATTY. DOCKET NO.

SERIAL NO.


LUD-5684.2 CIP

09/919,162

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use several sheets if necessary)

(37 CFR 1.98(b))



APPLICANT

RENAULD, et al.

FILING DATE

July 31, 2001

GROUP

UNKNOWN

U.S. PATENT DOCUMENTS

*Examiner Initial	Patent Number	Issue Date	Patentee	Class	Subclass	Filing Date (if appropriate)

FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION

	Document Number	Date	Country	Class	Subclass	Translation	
						Yes	No
	99/61617 ✓	12/2/99	WO				
	00/65027 /		WO				
	00/73457 ✓	12/7/00	WO				
	01/40467 ✓	6/7/01	WO				

OTHER DOCUMENTS

(INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)

✓	Parrish-Novak, et al., "Interleukin-21 and its receptor are involved in NK cell expansion and regulation of lymphocyte function," Nature 408:57-63 (November 2, 2000)
✓	Xie, et al., "Interleukin (IL-22), a Novel Human Cytokine That Signals Through the Interleukin Receptor-related proteins CRF 2-4 and IL-22R." J. Biol. Chem 275 (40):51335-51339 (October 6, 2000)

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.